Join our daily newsletter At The Bell to receive exclusive market insights
- Prescient Therapeutics (PTX) strikes a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its OmniCAR cell lines for its upcoming clinical trials
- The treatment will be studied against a range of cancers, but it is likely to be first used in Prescient’s acute myeloid leukemia trial
- Prescient says Q-Gen is one of Australia’s leading producers of cell-based medicines and will manufacture the treatment at its Brisbane facility
- The five-year agreement will cover the manufacture and delivery of autologous OmniCAR-T cells for clinical trials
- Shares in PTX last traded at 18.5 cents on August 15
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its OmniCAR cell lines for its upcoming clinical trials.
The treatment will be studied against a range of cancers, but it is likely to be first used in Prescient’s acute myeloid leukemia trial.
PTX said Q-Gen was one of Australia’s leading producers of cell-based medicines and would manufacture the treatment at its Brisbane facility.
The five-year agreement will cover the manufacture and delivery of autologous OmniCAR-T cells for clinical trials.
CEO and Managing Director Steven Yatomi-Clarke said achieving the first human studies of OmniCAR would be an important milestone for the company.
“This important agreement secures Prescient’s crucial supply of OmniCAR cells for our clinical trials and ensures we are producing the best possible cell therapy products for doctors and patients living with hard-to-treat cancers,” he said.
Shares in PTX last traded at 18.5 cents on August 15.
